ATE243024T1 - Zusammensetzung zur kontrollierten freisetzung - Google Patents

Zusammensetzung zur kontrollierten freisetzung

Info

Publication number
ATE243024T1
ATE243024T1 AT98900793T AT98900793T ATE243024T1 AT E243024 T1 ATE243024 T1 AT E243024T1 AT 98900793 T AT98900793 T AT 98900793T AT 98900793 T AT98900793 T AT 98900793T AT E243024 T1 ATE243024 T1 AT E243024T1
Authority
AT
Austria
Prior art keywords
controlled release
composition
release composition
active material
biologically active
Prior art date
Application number
AT98900793T
Other languages
English (en)
Inventor
Kare Larsson
Helena Ljusberg-Wahren
Niels Krog
Original Assignee
Gs Dev Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gs Dev Ab filed Critical Gs Dev Ab
Application granted granted Critical
Publication of ATE243024T1 publication Critical patent/ATE243024T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
AT98900793T 1997-01-13 1998-01-08 Zusammensetzung zur kontrollierten freisetzung ATE243024T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9700061A SE511313C2 (sv) 1997-01-13 1997-01-13 Komposition med reglerad frisättning innefattande fettsyraester av diacylglycerol
PCT/SE1998/000009 WO1998030206A1 (en) 1997-01-13 1998-01-08 Controlled release composition

Publications (1)

Publication Number Publication Date
ATE243024T1 true ATE243024T1 (de) 2003-07-15

Family

ID=20405393

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98900793T ATE243024T1 (de) 1997-01-13 1998-01-08 Zusammensetzung zur kontrollierten freisetzung

Country Status (9)

Country Link
US (1) US6660278B1 (de)
EP (1) EP0954287B1 (de)
JP (1) JP2001508773A (de)
AT (1) ATE243024T1 (de)
AU (1) AU5583298A (de)
CA (1) CA2277377C (de)
DE (1) DE69815659T2 (de)
SE (1) SE511313C2 (de)
WO (1) WO1998030206A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020153508A1 (en) 2000-06-29 2002-10-24 Lynch Matthew Lawrence Cubic liquid crystalline compositions and methods for their preparation
US6946137B2 (en) * 2001-10-19 2005-09-20 Idexx Laboratories, Inc. Methods for the controlled delivery of pharmacologically active compounds
AU2002335077B2 (en) 2001-10-19 2006-09-07 Idexx Laboratories, Inc. Injectable compositions for the controlled delivery of pharmacologically active compound
US7439268B2 (en) * 2003-07-18 2008-10-21 Idexx Laboratories Compositions containing prodrugs of florfenicol and methods of use
US20050049210A1 (en) * 2003-08-27 2005-03-03 Idexx Laboratories, Inc. Methods for the controlled delivery of pharmacologically active compounds
AU2005249274B2 (en) * 2004-06-04 2011-02-24 Camurus Ab Liquid depot formulations
WO2006036984A2 (en) 2004-09-28 2006-04-06 Atrium Medical Corporation Stand-alone film and methods for making the same
US9012506B2 (en) 2004-09-28 2015-04-21 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US9801982B2 (en) 2004-09-28 2017-10-31 Atrium Medical Corporation Implantable barrier device
US9000040B2 (en) 2004-09-28 2015-04-07 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
WO2006036982A2 (en) 2004-09-28 2006-04-06 Atrium Medical Corporation Drug delivery coating for use with a stent
US20060127437A1 (en) * 2004-12-13 2006-06-15 Misty Anderson Kennedy Semisolid system and combination semisolid, multiparticulate system for sealing tissues and/or controlling biological fluids
US8535709B2 (en) * 2004-12-13 2013-09-17 Southeastern Medical Technologies, Llc Agents for controlling biological fluids and methods of use thereof
US20070059350A1 (en) * 2004-12-13 2007-03-15 Kennedy John P Agents for controlling biological fluids and methods of use thereof
US8288348B2 (en) * 2005-07-13 2012-10-16 Allergan, Inc. Cyclosporin compositions
US9427423B2 (en) 2009-03-10 2016-08-30 Atrium Medical Corporation Fatty-acid based particles
US9278161B2 (en) 2005-09-28 2016-03-08 Atrium Medical Corporation Tissue-separating fatty acid adhesion barrier
EP1933991A4 (de) 2005-10-15 2012-05-02 Atrium Medical Corp Hydrophobe vernetzte gele für bioabsorbierbare arzneimittelträgerüberzüge
WO2008057328A2 (en) 2006-11-06 2008-05-15 Atrium Medical Corporation Tissue separating device with reinforced support for anchoring mechanisms
US9492596B2 (en) 2006-11-06 2016-11-15 Atrium Medical Corporation Barrier layer with underlying medical device and one or more reinforcing support structures
US7550625B2 (en) * 2007-10-19 2009-06-23 Idexx Laboratories Esters of florfenicol
WO2010063080A1 (en) 2008-12-05 2010-06-10 Commonwealth Scientific And Industrial Research Organisation Amphiphile prodrugs
US20110038910A1 (en) 2009-08-11 2011-02-17 Atrium Medical Corporation Anti-infective antimicrobial-containing biomaterials
WO2011050388A1 (en) * 2009-10-30 2011-05-05 Monash University Liquid crystal composition and method of use
EP2574337B1 (de) * 2010-05-18 2018-05-09 FUJIFILM Corporation Karotinoidhaltige zusammensetzung und herstellungsverfahren dafür
EP2593141B1 (de) 2010-07-16 2018-07-04 Atrium Medical Corporation Zusammensetzung und verfahren zur veränderung der geschwindigkeit einer hydrolyse ausgehärteter materialien auf ölbasis
US9867880B2 (en) 2012-06-13 2018-01-16 Atrium Medical Corporation Cured oil-hydrogel biomaterial compositions for controlled drug delivery
EP3326613A1 (de) 2012-07-26 2018-05-30 Camurus AB Opioid-formulierungen
BR112020010519A2 (pt) 2017-11-27 2020-10-20 Umecrine Cognition Ab formulação farmacêutica de oxima de 3¿lfa-etinil-3¿eta-hidroxiandrostan-17-ona
US20210275489A1 (en) 2018-06-21 2021-09-09 NanoMed Holdings Pty Ltd Platinum-based amphiphile prodrugs
WO2022161558A1 (de) * 2021-01-29 2022-08-04 Ioi Oleo Gmbh Polyglycerolfettsäureesterhaltige zusammensetzung

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5321393B2 (de) * 1974-10-19 1978-07-03
US5264460A (en) * 1988-05-30 1993-11-23 Deutsche Solvay-Werke Gmbh Process for preparing nonionic surfactants
GB2222770B (en) 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
IE65045B1 (en) 1990-04-28 1995-10-04 Takeda Chemical Industries Ltd Granulated preparations and method of producing the same
AU668509B2 (en) 1991-04-19 1996-05-09 Affinity Biotech, Inc. Convertible microemulsion formulations
SE518578C2 (sv) * 1994-06-15 2002-10-29 Gs Dev Ab Lipidbaserad komposition
US6013269A (en) * 1994-10-12 2000-01-11 The Procter & Gamble Company Cosmetic make-up compositions
SE504582C2 (sv) 1995-07-06 1997-03-10 Gs Dev Ab Cyklosporinkomposition baserad på en L2-fas
CZ288739B6 (cs) * 1996-08-01 2001-08-15 Galena, A. S. Cyklosporin obsahující léčivé přípravky

Also Published As

Publication number Publication date
US6660278B1 (en) 2003-12-09
EP0954287B1 (de) 2003-06-18
SE9700061D0 (sv) 1997-01-13
EP0954287A1 (de) 1999-11-10
SE511313C2 (sv) 1999-09-06
CA2277377C (en) 2007-12-18
AU5583298A (en) 1998-08-03
DE69815659D1 (de) 2003-07-24
SE9700061L (sv) 1998-07-14
WO1998030206A1 (en) 1998-07-16
JP2001508773A (ja) 2001-07-03
DE69815659T2 (de) 2004-04-29
CA2277377A1 (en) 1998-07-16

Similar Documents

Publication Publication Date Title
DE69815659D1 (de) Zusammensetzung zur kontrollierten freisetzung
ES2153355T3 (es) Procedimiento para la preparacion de microesferas que contienen compuestos biologicamente activos.
TR199701277T1 (xx) Biyoaktif bile�ikler olarak ya� asidi esterleri.
IL106248A (en) Adhesive compositions and method of bonding biological tissue to a substance
PT774962E (pt) Utilizacao de dha como uma composicao farmaceutica
HUP0000937A2 (hu) Új zsírsav-származékok
AU561811B2 (en) Organic amide compounds derived from nitrogenous lipids
EP0152281A3 (de) Transdermale Nicardipinhydrochlorid-Formulierung
BR9808668A (pt) Suspensão aquosa de microcápsulas compreendendo um material biologicamente ativo, e, processos para preparação de uma suspensão aquosa de microcápsulas aderentes e para aplicação de microcápsulas em um substrato pretendido
DK0549774T3 (da) Anvendelse af porøst calciumcarbonat som bærermateriale for in vitro cellekulturer
AU3145995A (en) Indolizine spla2 inhibitors
MY110984A (en) Immobilized lipases
BR9305636A (pt) Composição compreendendo TCMTB em um portador sólido e métodos para fazer uma composição compreendendo TCMTB e um portador sólido e para impedir o crescimento de um microorganismo.
JPS57117868A (en) Method of combining biological active substance to carrier containing hydroxyl group
ES2185003T3 (es) Procedimiento para la desintegracion de acidos nucleicos en materiales biologicamente activos.
ES2103369T3 (es) Derivados de lanolina como sustancias que aceleran la penetracion y su aplicacion en sustancias farmaceuticas u otras formulaciones que contienen sustancias biologicamente activas.
BR9205903A (pt) Sistema de retardamento aperfeiçaodos para a liberação retardada de substancias valiosas medicinais e/ou biológicas a partir de um materialde suporte de depósito
GB2324528A (en) Cytostatic hydroxamic acid derivatives
ES2189014T3 (es) Procedimiento para insomerizacion de alcoholes alilicos.
DE69928524D1 (de) Biologisch aktive zusammensetzung
ATE267401T1 (de) Technik zur mikroverkapselung von markierungen
EP0997735A3 (de) Stabilisierung von biologischen Flüssigkeiten durch Zusatz von Sterinestern
KR970705381A (ko) 흡수성 첨가제를 함유하는 에스트라디올 트랜스더멀 치료 시스템
ID20810A (id) Metoda merawat luka dangkal tidak dijahit dengan menggunakan komposisi ester siano akrilat terdiri dari bahan anti mikroba
UA19786A (uk) Засіб для обробки бульб кортоплі перед посадкою

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties